Skip to main content

Table 1 Demographic characteristics of patients with device-associated osteomyelitis treated with daptomycin in the CORE database

From: A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin

Characteristic No follow-up in CORE 2009 Evaluable population
PJI OHAO
(n = 32) (n = 27)a (n = 21)a
Sex, n (%)    
  Female 18 (56.3) 12 (44.4) 12 (57.1)
  Male 14 (43.8) 15 (55.6) 9 (42.9)
Median weight, kg (range) 81.4 (37.1–120.0) 86.4 (44.1–128.9) 79.0 (40.0–136.4)
Age group (y), n (%)    
   ≤ 50 6 (18.8) 4 (14.8) 13 (61.9)
  51–65 14 (43.8) 12 (44.4) 7 (33.3)
   ≥ 66 12 (37.5) 11 (40.7) 1 (4.8)
In community 48 h prior to receiving daptomycin, n (%) 15 (46.9) 13 (48.1) 11 (52.4)
ICU stay during daptomycin, n (%) 7 (21.9) 1 (3.7) 0 (0.0)
Initial creatinine clearance 5 (15.6) 2 (7.4) 0 (0.0)
< 30 mL/min, n (%)
Surgical intervention, n (%) 22 (68.8) 22 (81.5) 17 (81.0)
At least 1 pathogen identified, n (%) 22 (68.8) 20 (74.1) 18 (85.7)
Median initial daptomycin dose, mg/kg (range) 6 (4–13.5) 6 (4–9) 6 (4–8)
Median duration of daptomycin, days (range) 35 (2–78) 41 (6–70) 40 (8–62)
  1. CORE Cubicin® Outcomes Registry and Experience, ICU intensive care unit, OHAO other hardware-associated osteomyelitis, PJI prosthetic joint infection
  2. aOne patient in each of the PJI and OHAO groups was not included in the evaluable population